Breaking News, Collaborations & Alliances

HBM Alpha Therapeutics Strikes $395M Deal for CRH Antibody Therapy

Signs a strategic collaboration and license agreement to advance novel therapies targeting corticotropin-releasing hormone (CRH) for various disorders.

Author Image

By: Charlie Sternberg

Associate Editor

HBM Alpha Therapeutics (HBMAT) Inc., a biotechnology company incubated by Harbour BioMed, has entered a strategic collaboration and license agreement with a business partner to advance novel therapies targeting corticotropin-releasing hormone (CRH) for various disorders. Under the agreement, the partner gains exclusive global rights, excluding Greater China (mainland China, Taiwan, Hong Kong, and Macau), to develop and commercialize HAT001 (designated as HBM9013 by Harbour BioMed), a potent a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters